[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of California, Davis\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":593},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,131,0,25,[9,40,66,95,126,151,176,202,222,243,273,296,315,337,356,375,397,418,438,461,480,499,521,549,565],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100616315",false,"NCT07304011","Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent","A Phase 2 Study of Olutasidenib in Combination With Azacitidine Followed by Olutasidenib Maintenance After Venetoclax Plus a Hypomethylating Agent Regimen (HMA-VEN) for IDH1-Mutated Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n* Pathologically documented AML (except acute promyelocytic leukemia with the t(15;17) translocation) as defined by the World Health Organization (WHO) or International Consensus Classification criteria\n* Achieved complete response (CR)\u002Fcomplete remission with incomplete count recovery (CRi) response to first line HMA-Ven according to the European Leukemia Net (ELN) recommendations for diagnosis as determined by investigator review\n* Documented IDH1-R132 mutations (≥ 0.01%) detected in the bone marrow or blood. Mutation must be present at the time of AML diagnosis or after initiating HMA-Ven\n* Receiving first-line HMA-Ven with less than or equal to 4 cycles of HMA-Ven at the time of enrollment. Participants must discontinue venetoclax (Ven) at least 1 week (or 5 half-lives, whichever is shorter) from initiating study treatment\n* Candidate for standard of care azacitidine\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 50%)\n* No prior solid organ allograft\n* Recovery from the non-hematologic toxic effects of prior treatment to grade ≤ 1, or baseline value according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) classification (excluding infertility or alopecia)\n* Aged ≥ 18 at the time of consent\n* Creatinine clearance ≥ 40 mL\u002Fmin (calculated by the Cockcroft-Gault formula or measured by 24-hour urine collection)\n* Serum alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN)\n* Serum aspartate aminotransferase (AST) ≤ 3 × ULN\n* Bilirubin ≤ 2 x ULN unless due to Gilbert's syndrome or controlled autoimmune hemolytic anemia (not requiring immunosuppressive other than ≤ 20 mg of prednisolone daily)\n\n  * Note: Patients with Gilbert's syndrome may be included if total bilirubin is ≤ 3 × ULN and direct bilirubin is ≤ 2 × ULN\n* Prothrombin time (PT) or international normalized ratio (INR)\u002Factivated partial thromboplastin time (aPTT) ≤ 1.5 × ULN\n* Women of child-bearing potential, men, and their respective partners, must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose of olutasidenib\n* Must sign and date the informed consent form prior to undergoing any study procedures\n\nExclusion Criteria:\n\n* Prior IDH1 inhibitor (IDH1i) targeted therapy\n* Prior AML therapy except for HMA-Ven\n* History of a different malignancy unless they have been disease-free for at least 12 months and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with a history of other malignancies within 12 months and without any evidence of disease progression or requiring therapy may be considered, but only after consideration and approval by the Overall Principal Investigator (PI). Individuals with the following cancers are eligible if diagnosed and\u002For treated within the past 12 months: cervical cancer in situ, breast ductal carcinoma in situ (DCIS), and basal cell or squamous cell carcinoma of the skin\n* Patients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy\n* Patients with previous allogeneic hematopoietic stem cell transplantation (HSCT) for non-AML indications, if they meet any of the following criteria: \\\u003C 100 days from time of HSCT; active acute or chronic graft versus (vs.) host disease (GvHD); or receiving immunosuppressive therapy as treatment or prophylaxis against GvHD\n\n  * Note: Doses \\\u003C 20 mg methylprednisolone (or its equivalent) daily are not an exclusion criterion\n* Treatment with radiation therapy or major surgery (requiring general anesthesia) within 2 weeks prior to study drug dosing\n* Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption\n* Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris; previous history of myocardial infarction within one year prior to study entry, uncontrolled hypertension, or uncontrolled arrhythmias\n* Patients with a baseline corrected QT interval by Fridericia's formula (QTcF) of \\> 480 msec\n\n  * Note: This criterion does not apply to patients with a bundle branch block (BBB); for participants with BBB, a cardiology consult is recommended to ensure that QTcF is not prolonged\n* Concomitant medication(s) known to cause Torsades de Pointes (TdP) initiated less than the duration required to reach steady-state plasma concentration (approximately five half-lives) before first dose of study drug. Medications used as needed (PRN), e.g. Zofran, and common AML supportive care drugs (e.g. levofloxacin, azoles, etc.) are exempt\n* Concurrent treatment with chronic corticosteroids except if chronic treatment with \\\u003C 20 mg of methylprednisolone daily or equivalent (pulse steroids for treatment or prophylaxis are allowed \\[e.g., for transfusion or medication reactions\\])\n* Known history of seropositivity for HIV infection\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy (prophylactic systemic antimicrobials permitted)\n* Uncontrolled disease-related metabolic disorder (e.g., hypercalcemia)\n* Pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial or within 90 days after the last dose of olutasidenib. Pregnant or breastfeeding\n\n  * NOTE: Breast milk cannot be stored for future use while the mother is being treated on study)\n* Plans to donate sperm or conceive a child through intercourse while enrolled in this trial or within 90 days after the last dose of olutasidenib\n* Unwillingness or inability to comply with procedures either required in this protocol or considered standard of care\n* Medical, uncontrolled disease-related metabolic disorder, psychiatric, cognitive, or other conditions that may, in the opinion of the investigator, compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol, or complete the study","ALL","18 Years",{"count":19,"type":20},28,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azacitidine may inhibit the growth of cancer cells by blocking certain enzymes required for cell growth. Maintenance therapy can help prevent or delay cancer from coming back. Olutasidenib with azacitidine followed by olutasidenib maintenance may be effective in treating patients with IDH1-mutated AML who have received prior HMA-Ven.",[26],"Acute Myeloid Leukemia","RECRUITING","2026-06-30",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":31},"2025-12-17",{"date":35,"type":20},"2029-12-01",{"name":37,"class":38},"University of California, Davis","OTHER",1,{"id":41,"slug":4,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100523866","NCT06101277","Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)","LIVELONG","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed cancers:\n\n   1. Cohort A: (Cohort removed in protocol version 4.0)\n   2. Cohort B: Small bowel\n   3. Cohort C: Pancreatic and ampullary, colorectal, and appendiceal\n   4. Cohort D: (Cohort removed in protocol version 4.0)\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":47,"type":20},300,[49],"NA","This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.",[52,53,54,55,56,57,58,59],"Small Bowel Cancer","Colorectal Cancer","Appendiceal Cancer","Biliary Cancer","Gall Bladder Cancer","Intrahepatic Cholangiocarcinoma","Extrahepatic Cholangiocarcinoma","Oligoprogressive",{"date":30,"type":31},{"date":62,"type":31},"2023-10-05",{"date":64,"type":20},"2039-09-15",{"name":37,"class":38},{"id":67,"slug":4,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100642037","NCT07660120","CO2 LADD TAC With and Without 5-FU for Hypertrophic Burn Scars: A Triple-Blinded, Split Scar RCT","Comparing the Safety and Efficacy of CO2 Laser-Assisted Triamcinolone Delivery With and Without 5-Fluorouracil for Hypertrophic Burn Scars: A Triple-Blinded, Randomized Split Scar Clinical Trial","Inclusion Criteria:\n\n* Patient with hypertrophic scarring secondary to burn injury\n* Ages 18-89\n\nExclusion Criteria:\n\n* Pregnant patients or patients of childbearing age, sexually active, and unwilling to utilize contraception\n* Children\n* Individuals that are cognitively impaired and unable to provide consent\n* Currently breastfeeding\n* Has taken oral retinoids within 6 months of study initiation\n* Prior laser or intralesional TAC\u002F5-FU treatments for their hypertrophic scars\n* Active infection\n* Active malignancy\n* Known hypersensitivity to CO2 laser, TAC, or 5-FU\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency (complete or partial), due to risk of systemic 5-FU toxicity\n* Systemic corticosteroid or immunosuppressive medication use\n* Intolerance to anesthesia\n* Known connective tissue disease","89 Years",{"count":74,"type":20},65,[49],"Burn scars can sometimes heal in a way that causes them to become thick, raised, and stiff. These scars may itch, feel uncomfortable, limit movement, and affect how the skin looks. Because of this, many burn survivors look for treatments that can help improve both the appearance and the symptoms of their scars.\n\nOne treatment that has shown promise is fractional CO₂ laser therapy. This laser creates tiny openings in the scar tissue that help soften the scar and stimulate the skin to remodel itself. These openings can also help medications applied to the skin reach deeper into the scar where they may work better.\n\nA steroid medication called triamcinolone is commonly used to treat these scars. Another medication, called 5-fluorouracil (5-FU), has been shown in prior studies to work well when combined with steroids, but it is usually given by injection, which can be painful and sometimes causes side effects.\n\nIn this study, we will look at whether delivering these medications through the laser openings can improve scars more effectively. Each participant's scar will be divided into two halves. One side will receive both medications, and the other side will receive the steroid alone. By comparing the two sides of the same scar, we hope to better understand whether adding 5-FU provides additional benefit.",[78,79,80,81],"Burn","Hypertrophic Scars","Scar Improvement by Laser","CO2 Laser in Scars",[83,84,85,86],"burn scar","hypertrophic scar","CO2 Laser","laser assisted drug delivery","NOT_YET_RECRUITING","2026-06-29",{"date":90,"type":31},"2026-07-01",{"date":90,"type":20},{"date":93,"type":20},"2028-07-10",{"name":37,"class":38},{"id":96,"slug":4,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":39},"100641721","NCT07660315","Goji Berry and Vasomotor Symptoms Pilot Study","GOJI-VMS Pilot Study: Effects of Two Goji Berry Powder Forms on HDL Function, Vasomotor Symptoms, and Cognitive Performance","GOJI-VMS","Inclusion Criteria:\n\n* Adult women aged 40-65 years\n* Peri- or postmenopausal with vasomotor symptoms (hot flashes) occurring ≥4 days\u002Fweek over the past 2 weeks\n* Willing to consume one mug-cake daily for 30 days\n* Willing to complete daily VMS symptom tracking on a smartphone\n* Hormone therapy (HRT) is allowed if the dose has been stable for ≥8 weeks and hot flashes are still present\n\nExclusion Criteria:\n\n* Combined intake of \\>5 servings of eggs or lutein\u002Fzeaxanthin-rich vegetables per week\n* Current pregnancy or breastfeeding\n* Known allergy or intolerance to goji (Lycium barbarum) or to key mug-cake ingredients (e.g., wheat\u002Fgluten, dairy, and eggs)\n* Current use of warfarin (goji has reported interactions with anticoagulants); other anticoagulants will be reviewed case-by-case\n* Uncontrolled thyroid disease or other medical conditions likely to confound VMS assessment\n* Initiation or planned change of HRT, GLP-1 agonists, or other medications known to affect lipid metabolism or VMS during the 30-day study\n* Current participation in another interventional study\n* Any condition that, in the judgment of investigators, makes participation unsafe or data interpretation unreliable",true,"FEMALE","40 Years","65 Years",{"count":107,"type":20},6,[49],"The goal of this clinical trial is to compare two forms of goji berry powder-whole goji berry powder and goji juice powder-in peri- and postmenopausal women aged 40-65 years who experience frequent vasomotor symptoms (hot flashes). The study aims to determine which formulation is more promising for a future larger trial by evaluating effects on HDL cholesterol function, vasomotor symptoms, cognitive performance, and participant acceptability.\n\nThe main questions it aims to answer are:\n\nDoes whole goji berry powder produce a greater improvement in HDL cholesterol efflux capacity (CEC) over 30 days compared with goji juice powder? Are changes in HDL function associated with changes in hot flash burden, cognitive performance, and self-reported cognitive symptoms?\n\nResearchers will compare participants assigned to whole goji berry powder with participants assigned to goji juice powder to evaluate differences in HDL function, vasomotor symptoms, cognitive outcomes, and intervention acceptability.\n\nParticipants will:\n\nConsume one mug cake containing their assigned goji powder daily for 30 days. Record hot flash frequency, duration, and severity using a smartphone-based electronic diary.\n\nAttend study visits at baseline, Day 15, and Day 30. Provide fasting blood samples at baseline and Day 30 for assessment of HDL cholesterol efflux capacity and cardiometabolic biomarkers.\n\nComplete computerized cognitive testing (TabCAT) at baseline and Day 30. Complete questionnaires assessing menopause-related quality of life, brain fog, mental alertness, physical activity, and study acceptability.",[111],"Vasomotor Symptoms",[113,111,114,115,116,117,118,119],"Goji Berry","Hot flush","Lutein","Zeaxanthin","Carotenoids","HDL","Cholesterol Efflux Capacity",{"date":90,"type":31},{"date":122,"type":20},"2026-06-25",{"date":124,"type":20},"2027-10-31",{"name":37,"class":38},{"id":127,"slug":4,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":39},"100631414","NCT07500363","Improving Caregiver Engagement in Early Interventions","Improving Caregiver Engagement in Early Interventions for Autistic Children Using a Mobile Health Approach","Providers' eligibility criteria\n\n1. currently providing early intervention services, including a caregiver-coaching component\n2. having at least 1 child in the autism service classification on their caseload.\n\nCaregiver\u002FChild Dyads eligibility criteria\n\n1. child is 12-60 months of age at the time of enrollment\n2. child has a diagnosis or high likelihood of autism\n3. a family\u002Ffriend supporter of the caregiver is willing to be part of the study\n4. caregivers and supporters speak English","12 Months",{"count":19,"type":20},[49],"The goal of this study is to test the effectiveness of the FANS-EI program in supporting caregiver engagement in caregiver-mediated early interventions for young children with autism. This study also examines caregiver-perceived social support and self-efficacy and FANS-EI implementation outcomes (feasibility, acceptability, appropriateness).",[137],"Autism",[139,140,141,142,143],"Early Intervention","Caregiver Mediated Interventions","caregiver engagement","mobile health","social support","2026-06-26",{"date":88,"type":31},{"date":147,"type":20},"2026-07",{"date":149,"type":20},"2028-12",{"name":37,"class":38},{"id":152,"slug":4,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100589949","NCT06961058","Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department","In Person vs Telehealth Opioid Use Disorder Treatment After Patients Leave the Emergency Department","TREATED","Inclusion Criteria:\n\n* Adult patients who present to the emergency department and receive buprenorphine (either administered or prescribed) to treat OUD\n* do not have an established outpatient clinic where they will get buprenorphine when they leave the emergency department\n\nExclusion Criteria:\n\n* inability to give consent\n* patients living in institutions (e.g., nursing homes, prisons)\n* unable to complete questionnaires in either English or Spanish",{"count":159,"type":20},528,[49],"Main study objective: compare long-term buprenorphine treatment outcomes for patients who start buprenorphine for opioid use disorder (OUD) in the emergency department and are then referred to get outpatient buprenorphine treatment either via telehealth or at an in-person clinic.\n\nResearchers will:\n\nCompare rates of establishing outpatient OUD treatment, how long patients stay on buprenorphine, and patients' experience with care to determine whether patient experiences and outcomes are better for patients referred to telehealth treatment versus patients patients referred to in-person treatment after they leave the emergency department.\n\nParticipants will:\n\nBe recruited from 3 different hospital emergency departments.\n\nAnswer questionnaires at baseline and then 1, 3, 6, and 9 months after their initial emergency department visit.",[163],"Opioid Use Disorder",[165,166,167,168],"emergency department","buprenorphine","telehealth","comparative effectiveness",{"date":88,"type":31},{"date":171,"type":31},"2025-06-03",{"date":173,"type":20},"2029-09-01",{"name":37,"class":38},3,{"id":177,"slug":4,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":102,"sex":16,"minAge":104,"maxAge":72,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":39},"100582581","NCT06865170","Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?","Inclusion Criteria:\n\n1. age ≥ 40 years\n2. fulfillment of the American College of Rheumatology criteria for knee OA\n3. confirmation of knee-related pain and\u002For functional loss by clinical examination.\n4. Patients with either\n\n   1. bilateral knee OA\u002Finjections, or\n   2. unilateral knee OA\u002Finjections.\n5. Agreed to an intra-articular knee joint injection with steroids\n6. Naive to use of ethyl chloride\n\nExclusion Criteria:\n\n1. Arthroscopy of the index knee(s) within the prior 6 months\n2. Steroid injection of the knee(s) within the prior 3 months\n3. Hyaluronic acid or platelet-rich plasma injection of the knee within the prior 6 months\n4. Patient reported prior injection of any type with ethyl chloride spray\n5. Knee effusion requiring aspiration at the time of the procedure\n6. Cognitively impaired individuals",{"count":182,"type":20},88,[184],"PHASE4","This study aims to investigate factors that affect the subjective experience of pain during and after intra-articular knee joint injection of steroids by comparing needle gauge size (22 G vs 25 G needles), as well as the presence or absence of topical ethyl chloride spray. Additionally, this study will investigate the effects of other various factors on patients' pain associated with the injection. Lastly, this study aims to determine the effect of patients' subjective pain from the injection on long-term clinical outcomes.\n\nSpecific aims are as follows:\n\nAim 1): Determine the effect of needle gauge size on patient reported pain associated with an ultrasound-guided intra-articular knee injection.\n\nAim 2): Determine the effect of ethyl chloride spray on patient reported pain associated with an ultrasound-guided intra-articular knee injection.\n\nAim 3): Determine the effect of sex, age, BMI, thigh size, severity of OA, and fear of needles on patient pain associated with an ultrasound-guided intra-articular knee injection.\n\nAim 4) Determine the effect of patient pain from the procedure on longer term clinical outcomes after an ultrasound-guided intra-articular knee steroid injection.\n\nResearchers will obtain data at various time points, including pre-procedural data, immediately after the procedure, 24-48 hours after, and 6 weeks post-procedure.\n\nParticipants will:\n\nConsent to receiving an intra-articular knee joint injection with steroids if indicated.\n\nScore their \"procedural\" pain immediately following the procedure, score their post-procedural \"soreness\" 24-48 hours after via telephone call, and score their overall knee pain about 6 weeks after the procedure via telephone call.",[187,188],"Osteoarthritis (OA) of the Knee","Fear of Needles",[190,191,192,193,194,195],"pain perception","fear of needles","needle gauge","ethyl chloride","corticosteroid injection","25G versus 22G",{"date":88,"type":31},{"date":198,"type":20},"2026-08",{"date":200,"type":20},"2026-12",{"name":37,"class":38},{"id":203,"slug":4,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":102,"sex":16,"minAge":17,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":39},"100526696","NCT06138106","Developing a Nutritional Supplement to Increase Collagen Synthesis in People","Inclusion Criteria:\n\n* Young healthy adults (18-30 y)\n\nExclusion Criteria:\n\n* Pregnancy\n* Smoking\n* Receiving any medication that may interfere with the study outcomes","30 Years",{"count":209,"type":20},20,[49],"The purpose of this study is to test whether a natural product supplement can potentiate the increase in collagen synthesis following the ingestion of collagen protein. The investigators have developed a model of natural (GRAS certified) products that stimulate collagen synthesis, in vitro. The investigators will determine whether the natural product supplement can potentiate the collagen synthetic response to the ingestion of collagen protein. Basal and fed serum will be isolated and these samples will be used to treat human engineered ligaments.",[213,214,215],"Dietary Supplements","Connective Tissue","Exercise",{"date":88,"type":31},{"date":218,"type":31},"2023-11-21",{"date":220,"type":20},"2026-12-01",{"name":37,"class":38},{"id":223,"slug":4,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":39},"100645229","NCT07677839","UHFUS Characterization of Normal Lymphatic Anatomy","Redefining the Normal: Ultra-High Frequency Ultrasound Characterization of Lymphatic Anatomy in Patients With Breast Cancer","UHFUS","Inclusion Criteria:\n\n* 1\\. Aged 18+ at the time of consent.\n* 2\\. Confirmed breast cancer diagnosis\n* 3\\. Planned ALND (CPT code: 38745) or SLNB (CPT code: 38900) for breast cancer treatment\n* 4\\. Provision of a signed and dated informed consent form.\n* 5\\. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n* 1\\. History of transient or permanent edema of the extremity, including edema ≥stage 1 per the International Society of Lymphology (ISL) staging system 15\n* 2\\. History of prior axillary nodal surgery\n* 3\\. History of any lymphatic disease or venous disease of the upper extremity, including deep venous thrombosis",{"count":230,"type":20},50,[49],"This is a prospective pilot study of breast cancer patients undergoing axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB). Participants will undergo ultra-high frequency ultrasound (UHFUS) imaging with indocyanine green (ICG) dye to map lymphatic channels between the wrist and elbow to investigate normal lymphatic anatomy in patients with breast cancer.",[234],"Breast Cancer",[236],"Breast cancer",{"date":90,"type":31},{"date":239,"type":31},"2026-06-17",{"date":241,"type":20},"2036-09-01",{"name":37,"class":38},{"id":244,"slug":4,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":39},"100585680","NCT06905509","Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation\u002F Maintenance in Relapsed\u002F Refractory Large B-Cell Lymphoma (R\u002FR LBCL)","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed R\u002FR LBCL\n\n  * Can include diffuse large B-cell lymphoma (DLBCL) (not otherwise specified \\[NOS\\] or with concurrent MYC and BCL2 rearrangements), high-grade B-cell lymphoma (HGBCL) (NOS or with MYC and BCL2 or BCL6 rearrangements) and transformed follicular lymphoma (FL) and nodal marginal zone lymphoma (MZL)\n  * Histological confirmed CD20+ relapsed\u002F refractory large cell lymphoma\n* Must have had relapsed or refractory disease following standard frontline chemotherapy. Refractory disease is defined as large cell lymphoma not achieving complete remission, progressing, or relapsing within 6 months after first-line chemotherapy based on PET\u002FCT per the Lugano criteria. Relapsed disease is defined as disease that recurs beyond 6 months after completion of initial chemotherapy based on PET\u002FCT per the Lugano criteria\n* Have received 1 or more prior lines of systemic therapy for the treatment of large cell lymphoma. NOTE: Prior radiation therapy or systemic corticosteroids will not be considered a line of therapy\n* Candidate for platinum-containing chemotherapy (RICE, RDHAP\u002FX, or R-Gem\u002FOx) pre-autologous hematopoietic cell transplantation (autoHCT) followed by autoHCT as per institutional guidelines\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)\n* Measurable disease via diagnostic quality CT or PET\u002FCT with at least 1 node having the longest diameter (LDi) greater than (\\>) 1.5 centimeter (cm) or 1 extranodal lesion with LDi \\> 1 cm (per the Lugano criteria 2014)\n* Aged ≥ 18 at the time of consent\n* Creatinine clearance (CrCl) ≥ 45 mL\u002Fmin (Cockcroft-Gault)\n* Serum alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN)\n* Serum aspartate aminotransferase (AST) ≤ 3 x ULN\n* Bilirubin ≤ 1.5 x ULN unless due to Gilbert's syndrome or controlled autoimmune hemolytic anemia (not requiring immunosuppressive other than ≤ 20 mg of prednisolone daily)\n\n  * Note: Patients with Gilbert's syndrome may be included if total bilirubin is ≤ 3 x ULN and direct bilirubin is ≤ 1.5 x ULN\n* Hemoglobin ≥ 8.0 g\u002FdL\n\n  * Note: Blood transfusion may be administered during Screening to meet this requirement only if anemia is due to marrow involvement of non-Hodgkin lymphoma (NHL)\n* Absolute neutrophil count ≥ 1000\u002FuL\n\n  * Note: Growth factor support is allowed to meet this requirement at Screening only if directly attributable to NHL infiltration of the bone marrow, proven by bone marrow biopsy\n* Platelet count ≥ 75,000\u002FuL or ≥ 50,000\u002FuL if bone marrow (BM) involvement or splenomegaly\n\n  * Note: Transfusion may be administered during screening to meet this requirement\n* prothrombin time (PT)\u002Finternational normalized ratio (INR)\u002Factivated partial thromboplastin time (aPTT) ≤ 1.5 x ULN\n* Note: If any of the above-mentioned cytopenias are present, there should be no evidence of myelodysplastic syndrome (MDS) or hypoplastic bone marrow\n* HIV-infected patients on effective anti-retroviral therapy with stable viral load and CD4 count for 1 year prior to enrollment are eligible for this trial. Testing for HIV viral load and antibody at screening is mandatory\n* Patients with a history of chronic hepatitis B virus (HBV) infection, must have an undetectable HBV viral load on suppressive therapy, if indicated. Patients with evidence of prior HBV but who are polymerase chain reaction (PCR)-negative are permitted in the trial but should receive prophylactic antiviral therapy. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial. Patients who received treatment for HCV that was intended to eradicate the virus may participate if hepatitis C ribonucleic acid (RNA) levels are undetectable. Testing for HBV and HCV is mandatory at screening\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 12 months after the last dose of epcoritamab\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n* Any adverse event (AE) related to the previous large cell lymphoma therapy which has not recovered to grade ≤ 1 (Common Terminology Criteria for Adverse Events \\[CTCAE\\] version \\[v.\\] 5.0) or baseline by cycle 1 day 1 (C1D1), except alopecia and non-clinically significant laboratory abnormalities\n* Uncontrolled intercurrent illness (including infection)\n* Known active central nervous system or meningeal (including leptomeningeal) involvement. Patients diagnosed with central nervous system (CNS) disease who achieved and maintained CNS complete response (CR) at the time of relapse are eligible. Lumbar puncture must be done in this case prior to study entry (within 90 days of enrollment) to demonstrate CNS CR status. Tests to investigate CNS involvement are required otherwise only if clinically indicated (i.e. disease suspected on basis of symptoms or other findings)\n* Receiving any other investigational treatments\n* Previous treatment with any bispecific T-cell engager with or without chemotherapy\n* Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of epcoritamab\n* Concurrent use of other anti-cancer agents or treatments except for certain therapeutics (e.g., prostate, breast hormonal-based therapy) per the treating physician's discretion\n\n  * Standard agents within 2 weeks or 5 half-lives, whichever is shorter, prior to the first dose of epcoritamab (excluding anti-CD20 monoclonal antibodies \\[mAbs\\], which can be administered until first full dose of epcoritamab); or\n  * CAR-T cell therapy within 30 days prior to the first dose of epcoritamab\n  * Palliative radiation is permitted only if on non-target lesions\n* Motor and sensory neuropathy grade ≥ 2 (CTCAE v.5.0)\n* Patients with a history of other malignancies, except adequately treated non-melanoma skin cancer, non-invasive superficial bladder cancer, curatively treated in-situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, localized low grade prostate cancer (up to Gleason score 6), or other solid tumors curatively treated with no evidence of disease for at least 3 years\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at trial enrollment or significant infections within 2 weeks prior to the first dose of epcoritamab\n* Confirmed history or current autoimmune disease or other diseases requiring permanent immunosuppressive therapy. Low-dose (10 mg\u002Fday) prednisolone (or equivalent) for rheumatoid arthritis or similar conditions is allowed\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)\n* Participant received any prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation\n* Autoimmune disease or other diseases that require continuous immunosuppressive therapy (except for prednisone doses of less than or equal to 10 mg, which is allowed)\n* Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia (requiring \\> 20 mg of prednisolone daily) or other concurrent uncontrolled medical conditions\n* Clinically significant cardiac disease including but not limited to:\n\n  * Unstable or uncontrolled disease\u002Fcondition related to or affecting cardiac function, e.g., unstable angina, congestive heart failure grade III or IV as classified by the New York Heart Association, uncontrolled clinically significant cardiac arrhythmia (CTCAE v 5.0 grade 2 or higher), or clinically significant electrocardiogram (ECG) abnormalities. Controlled New York Heart Association (NYHA) grade 1 or 2 are eligible\n  * Myocardial infarction, intracranial bleed, or stroke within the past 6 months\n  * Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) \\> 480 msec. NOTE: This criterion does not apply to participants with a left bundle branch block\n  * In case of any history of cardiovascular disease, a cardiology consult is required within 60 days prior to enrollment\n  * Age ≥ 75 and 2 or more active grade ≥ 2 cardiovascular conditions\n* Prior treatment with live, attenuated vaccines within 28 days prior to initiation of epcoritamab. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, bacillus Calmette-Guerin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Food and Drug Administration (FDA)-approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations allowed\n* Immune effector cell encephalopathy (ICE) score of less than 10 at study entry\n* Suspected allergies, hypersensitivity, or intolerance to epcoritamab or another anti-CD20 mAb or its excipients\n* Active HBV (DNA PCR-positive). Patients with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy\n* Active hepatitis C (RNA PCR-positive infection). Patients who received treatment for HCV that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable\n* Known history of seropositivity for HIV infection\n* Active cytomegalovirus (CMV) infection (PCR positive)\n* Pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial or within 12 months after the last dose of epcoritamab\n* Plans to donate sperm or conceive a child through intercourse while enrolled in this trial or within 12 months after the last dose of epcoritamab\n* Ongoing active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment (excluding prophylactic treatment) at the time of enrollment or within the previous 2 weeks prior to the first dose of epcoritamab\n* Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. If a subject has signs\u002Fsymptoms suggestive of SARS-CoV-2 infection or have had recent known exposure to someone with SARS-CoV-2 infection, the subject must have a negative molecular (e.g., PCR) test, or 2 negative antigen test results at least 24 hours apart, to rule out SARS-CoV-2 infection. Note: SARS-CoV-2 diagnostic tests should be applied following local requirements\u002Frecommendations. Subjects who do not meet SARS-CoV-2 infection eligibility criteria must be screen failed and may only rescreen per criteria\n* Suspected active or inadequately treated latent tuberculosis",{"count":7,"type":20},[23],"This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide \\[RICE\\], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP\u002FX\\] or gemcitabine and oxaliplatin \\[Gem\u002FOx\\]) and autologous hematopoietic cell transplant (HCT) works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab, a type of bispecific T-cell engager, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs, such as ifosfamide, etoposide phosphate, cytarabine, and gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. An autologous HCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving epcoritamab in combination with SOC platinum-based chemotherapy, such as RICE, RDHAP\u002FX and Gem\u002FOx, and autologous HCT may kill more cancer cells in patients with relapsed or refractory LBCL.",[253,254,255,256,257,258,259,260,261,262,263,264,265,266],"Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Nodal Marginal Zone Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",{"date":28,"type":31},{"date":269,"type":31},"2025-07-31",{"date":271,"type":20},"2030-08-01",{"name":37,"class":38},{"id":274,"slug":4,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":279,"minAge":17,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":39},"100529790","NCT06178354","Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer","A Pragmatic Phase 2 Study of Focal Ablation (Focal Cryotherapy or High Intensity Frequency Ultrasound) in Men With Clinically Localized Prostate Cancer","Inclusion Criteria:\n\n* Ability to understand and willingness to sign an informed consent form\n* Clinically localized grade group 1, 2, or 3 prostate cancer and unilateral magnetic resonance imaging (MRI) visible lesion(s). Up to 3 lesions will be allowed for focal treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥ 70%)\n* Patients ≥ 18 years of age at time of consent\n* Life expectancy ≥ 5 years\n* Ability and stated willingness to adhere to the study visit schedule and other protocol procedures\u002Frequirements for the duration of the study\n\nExclusion Criteria:\n\n* Nodal or distant metastases\n* Prior treatment for prostate cancer\n* Anticipated treatment with any cancer intervention, including radiation, hormonal therapy or surgery ≤ 6 months prior to focal therapy in this study\n* Known contraindications to general anesthesia\n* Uncorrectable coagulopathy\n* Significant active cardiac disease within the previous 6 months including: New York Heart Association (NYHA) class 4 congestive heart failure (CHF), unstable angina, or myocardial infarction\n* Any condition that would prohibit the understanding or rendering of informed consent\n* Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial","MALE",{"count":281,"type":20},100,[49],"This clinical trial evaluates the effectiveness of focal ablation with either focal cryotherapy or high intensity frequency ultrasound for the treatment of men with localized prostate cancer. Focal cryotherapy kills tumor cells by freezing them. High intensity frequency ultrasound uses highly focused ultrasound waves to produce heat and destroy tumor cells.",[285,286,287,288,289],"Localized Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8",{"date":28,"type":31},{"date":292,"type":31},"2023-11-09",{"date":294,"type":20},"2029-06",{"name":37,"class":38},{"id":297,"slug":4,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":50,"conditions":305,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":39},"100523867","NCT06101290","Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)","LAYOVER","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: prostate cancer\n   2. Cohort B: urothelial carcinoma\n   3. Cohort C: renal cell carcinoma\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":303,"type":20},150,[49],[306,59,307,308],"Prostate Cancer","Urothelial Carcinoma","Renal Cell Carcinoma",{"date":28,"type":31},{"date":311,"type":31},"2023-12-05",{"date":313,"type":20},"2035-01-15",{"name":37,"class":38},{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":336},"100485408","NCT05600686","Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed untreated DEL and DHL diffuse large B-cell lymphoma (DLBCL) meeting the World Health Organization (WHO) criteria for DEL - MYC greater than 40% and BCL2 greater than 50% by immunohistochemistry, or high-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements (double-hit and\u002For triple-hit are included)\n* Measurable disease by CT or PET\u002FCT scan, with one or more sites of disease \\>= 1.5 cm in longest dimension\n* Age \\>= 18 years at time of consent\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Life expectancy \\>= 6 months\n* Leukocytes \\>= 2,500\u002FuL\n* Absolute neutrophil count \\>= 1,000\u002FuL\n* Platelets \\>= 100,000\u002FuL\n* Hemoglobin \\>= 8 g\u002FdL\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\\\u003C 3 x ULN may be enrolled)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3 x ULN (AST and\u002For ALT =\\\u003C 5 x ULN for patients with liver involvement)\n* Alkaline phosphatase =\\\u003C 2.5 x ULN (=\\\u003C 5 x ULN for patients with documented liver involvement or bone metastases)\n* Creatinine clearance \\>= 30 mL\u002Fmin by Cockcroft-Gault\n* Activated partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)\n* Transthoracic echocardiography (TTE) or multigated acquisition scan (MUGA) ejection fraction greater than 40%\n* Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 7 months after the last dose of study drug\n* Ability to understand and the willingness to sign a written informed consent document\n* Human immunodeficiency virus (HIV) infected patients:\n\n  * No history of acquired immunodeficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200\u002Fmm\\^3 prior to beginning combination anti-retroviral therapy (ART)\n  * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n  * At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to \\>= 250\u002Fmm\\^3\n  * At the time of study entry, the HIV viral load must be undetectable by standard laboratory assay\n  * During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV positive (+) status\n  * No history of non-adherence to ART and willing to adhere to ART while on study\n  * Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed\n\nExclusion Criteria:\n\n* Current\u002F prior use of:\n\n  * Lymphoma treatment, except for:\n\n    * 1 cycle of DA-EPOCH-R or rituximab, cyclophosphamide, doxorubicin (Adriamycin) vincristine (Oncovin) and prednisolone (R-CHOP)\n    * Radiotherapy \\> 2 weeks of initiating study treatment\n    * Nitrosoureas or mitomycin C \\> 6 weeks of initiating study treatment\n    * Steroid treatment for DLBCL or steroid monotherapy to stabilize disease while awaiting fluorescence in situ hybridization (FISH)\n    * Other cancer therapies (e.g., prostate, breast hormonal-based therapy) per the principal investigator's discretion\n  * Anthracycline greater than 50 mg\u002Fm\\^2 (total lifetime) for a prior malignancy\n  * Complementary and alternative medications (CAM) within 1 week prior to initiating study treatment\n  * Treatment with any other investigational agent for any indication within 3 weeks prior to initiating study treatment\n  * Loncastuximab tesirine or rituximab with progression within 6 months of initiating study treatment\n  * Oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible\n  * Live, attenuated influenza vaccine within 4 weeks prior to initiating study treatment\n* Immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor, such as anti-tumor necrosis factor \\[TNF\\] agents) within 14 days prior to initiating study treatment. The following are exceptions to this criterion:\n\n  * Steroids\n  * Bisphosphonate therapy for symptomatic hypercalcemia or for other reasons (e.g., bone metastasis or osteoporosis)\n* Known uncontrolled central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement\n* History of hypersensitivity to anti-CD19 antibodies, loncastuximab tesirine, or any agents used in DA-EPOCH-R\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study\n* Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)\n* Breastfeeding or pregnancy\n* Clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; or inherited liver disease\n\n  * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \\[HbsAg\\] test and a positive anti-HBc \\[antibody to hepatitis B core antigen\\] antibody test) are eligible\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)\n* Documented eczema, psoriasis, or lichen simplex chronicus of vitiligo with dermatologic manifestations (e.g., patients with psoriatic arthritis would be excluded), unless the following apply:\n\n  * Affected skin covers less than 10% of body surface area (BSA)\n  * Disease is well controlled at baseline and only requires low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)\n  * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)\n* Known active tuberculosis (TB)\n* Severe infections within 4 weeks prior to initiating study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Major surgical procedure within 28 days prior to initiating study treatment or anticipation of need for a major surgical procedure during the course of the study\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":322,"type":20},24,[23],"This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.",[326,327,328,329],"Double-Expressor Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",{"date":28,"type":31},{"date":332,"type":31},"2023-05-24",{"date":334,"type":20},"2027-12-15",{"name":37,"class":38},2,{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":39},"100407612","NCT04587687","Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma","A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed\u002FRefractory Follicular Lymphoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed relapsed or refractory follicular CD30+ non-Hodgkin lymphoma (NHL) (included in this category are follicular grade I, II, IIIa). CD30 positivity \\> 1% (tumor cells or surrounding peripheral microenvironment)\n* Patients must have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease \\>= 1.5 cm in longest dimension\n* Relapsed or refractory disease after at least 1 prior regimen, defined using the 2014 Lugano classification\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Life expectancy of greater than 3 months\n* Leukocytes \\>= 2,500\u002FmcL\n* Absolute neutrophil count \\>= 1,000\u002FmcL\n* Platelets \\>= 50,000\u002FmcL\n* Hemoglobin \\>= 8 g\u002FdL\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\\\u003C 3 x ULN may be enrolled)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3 x ULN (AST and\u002For ALT =\\\u003C 5 x ULN for patients with liver involvement)\n* Alkaline phosphatase =\\\u003C 2.5 x ULN (=\\\u003C 5 x ULN for patients with documented liver involvement or bone metastases)\n* Creatinine clearance \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 by Cockcroft-Gault\n* Institutional normalized ratio (INR) and partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose.)\n* Administration of bendamustine or brentuximab vedotin may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells\u002FmcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy, or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C, steroid treatment for follicular lymphoma is allowed per protocol) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 2 weeks earlier. Specifically, the following therapies are not allowed:\n\n  * Herbal therapy (1 week washout required)\n  * Treatment with any other investigational agent within 3 weeks prior to cycle 1, day 1.\n  * Prior therapy with bendamustine or a bendamustine-containing regimens with progression within 6 months of receiving treatment\n* Current or prior use of immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 14 days prior to first dose (cycle 1, day 1). The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed 10 mg\u002Fday of prednisone or equivalent may be enrolled\n  * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\n  * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\n  * Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed\n* Patients with known uncontrolled central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement\n* History of hypersensitivity to bendamustine or brentuximab vedotin or any excipient\n* Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study\n* Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.\n\n  * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \\[HBsAg\\] test and a positive anti-HBc \\[antibody to hepatitis B core antigen\\] antibody test) are eligible.\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)\n* Neuropathy grade \\> 1\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n  * Rash must cover less than 10% of body surface area (BSA)\n  * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)\n  * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)\n* Patients with known active tuberculosis (TB) are excluded\n* Severe infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1\n* Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible\n* Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":344,"type":20},23,[23],"This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to determine if the combination of brentuximab vedotin plus bendamustine is safe and to determine the effectiveness of the combination.",[348,349],"Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma",{"date":88,"type":31},{"date":352,"type":31},"2020-12-04",{"date":354,"type":20},"2028-05",{"name":37,"class":38},{"id":357,"slug":4,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":39},"100644900","NCT07674927","Pilot Study Exploring the Effects of Rhythmic Auditory Stimulation on Gait in People With Motor Incomplete Spinal Cord Injury","Exploring the Effects of Rhythmic Auditory Stimulation on Gait in Motor Incomplete Spinal Cord Injury: A Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years old\n* Language: English or Spanish only\n* Diagnosis: non-progressive spinal cord lesion; classification as either grade C, D, or E SCI based on American Spinal Injury Association (ASIA) Impairment Scale (AIS)\n* Able to ambulate at least a contact guard assist level\n* Time post injury: ≥6 months\n* Cadence: minimum 40 steps\u002Fminute with clear heel strike\n* Able to consent\n\nExclusion Criteria:\n\n* Individuals who use an assistive device and are unable to achieve a 2-point walking pattern (left-right-left-right) with an assistive device\n* Walks exclusively with a 3-point walking pattern with an assistive device\n* Ambulation requiring a knee-ankle-foot orthosis (KAFO)\n* Presence of additional neurological or medical processes that contribute to weakness\n* Unable to perceive music through the MedRhythyms device",{"count":363,"type":20},15,[49],"This pilot study aims to evaluate the feasibility and preliminary efficacy of a wearable rhythmic auditory stimulation system, MedRhythms, for improving gait parameters in patients with motor incomplete SCI. Up to 15 participants aged 18 years or older with non-progressive SCI will be enrolled. Participants will complete supervised gait training using the MedRhythms device twice weekly during regularly scheduled physical therapy sessions over a six-week period. The device uses shoe-mounted sensors and headphones to deliver real-time individualized rhythmic auditory cues based on the user's gait pattern.\n\nPrimary outcome measures include change in walking speed assessed with the 10-Meter Walk Test. Secondary outcomes include walking endurance measured by the 6-Minute Walk Test, gait parameters obtained through GAITRite analysis, and participant-reported outcomes including the Walking Index for Spinal Cord Injury II (WISCI II) and the SCI Quality of Life Satisfaction with Social Roles and Activities measure. Outcomes will be assessed at baseline, post-intervention (6 weeks), and follow-up (12 weeks).\n\nFindings from this study will provide preliminary data on the feasibility and potential clinical impact of rhythmic auditory stimulation as an adjunctive gait rehabilitation strategy for individuals with incomplete SCI.",[367],"Spinal Cord Injury","2026-06-23",{"date":28,"type":31},{"date":371,"type":20},"2026-06-01",{"date":373,"type":20},"2026-12-31",{"name":37,"class":38},{"id":376,"slug":4,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":39},"100623532","NCT07397858","Cognition and Behavior With Sham Accelerated TMS","Studies of Cognition and Behavior Using Sham Accelerated Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* English speaking\n* Able to provide informed consent (and assent if \\\u003C 18 years)\n* 15-25 years old\n* Slight-to-severe symptoms of depression\n\nExclusion Criteria:\n\n* Past exposure to Transcranial Magnetic Stimulation\n* Unable to consent (due to medical condition, psychosis, substance use, etc)\n* Acute suicidal crisis or with active medical illness that would interfere with participation\n* Contraindications to receiving MRI as determined by screening questionnaires (Contraindications for MRI include metal in the body related to an injury or surgery, for example, surgical clips, metal fragments in the eyes, or piercings that cannot be removed. Subjects with braces or permanent retainers will not be scanned, because the effects on image signal are not well understood and may affect comparability between subjects and scan sites. Participants will be excluded for major neurological problems, such as seizure disorder, traumatic brain injury with loss of consciousness, or sensory problems that may impair task performance, such as blindness.)\n* Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies","15 Years","25 Years",{"count":7,"type":20},[49],"The goal of this clinical study is to understand how a person's expectations about treatment can influence their mood, motivation, and reactions to everyday rewards. The study includes young people ages 15-25 who will complete a sham (placebo) version of an accelerated transcranial magnetic stimulation (TMS) treatment. No active brain stimulation is given.\n\nThe main questions this study aims to answer are:\n\n1. Do expectancy and treatment beliefs change during and after an accelerated sham TMS schedule?\n2. Do these expectations influence mood, reward processing, or craving?\n3. Does a more intensive schedule of sham sessions lead to different expectancy effects than a slower, once-daily schedule?\n\nParticipants will:\n\n* Complete baseline clinical assessments and an MRI session\n* Undergo five days of accelerated sham TMS (no active brain stimulation is delivered)\n* Complete post-treatment MRI and follow-up assessments at 1 week and 4 weeks",[387],"Depression",[389,390],"TMS","Sham TMS",{"date":144,"type":31},{"date":393,"type":31},"2026-04-11",{"date":395,"type":20},"2028-01",{"name":37,"class":38},{"id":398,"slug":4,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":405,"phases":4,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":39},"100125345","NCT00899405","Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer","EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood","DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed lung cancer\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* May have received prior EGFR inhibitors",{"count":404,"type":20},800,"OBSERVATIONAL","RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.\n\nPURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.",[408],"Lung Cancer",[410],"lung cancer","2026-06-22",{"date":122,"type":31},{"date":414,"type":31},"2004-05-19",{"date":416,"type":20},"2034-05",{"name":37,"class":38},{"id":419,"slug":4,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":102,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":39},"100644430","NCT07663578","Cognitive and Electrophysiological Assessment of Non-Invasive Temporally-Interfering Electric Fields Stimulation (TIEFS)","TIEFS","Inclusion Criteria:\n\n* Adult patients (age 18-65 years of age) undergoing an intracerebral electrophysiology study for epilepsy pre-surgical evaluation are eligible for inclusion.\n* For healthy control subjects are also eligible for inclusion (Scalp EEG measurements).\n* Participants must be able to sufficiently speak and understand English or Spanish for consent and be able to understand and complete cognitive tasks.\n* All subjects must have the ability to give valid informed consent.\n\nExclusion Criteria:\n\n* No pregnant women will be recruited.\n* People with implanted electrical devices such as Deep Brain Stimulation devices or Pacemakers.\n* No prisoners will be recruited.",{"count":363,"type":20},[49],"The goal of this clinical trial is to learn how a non-invasive brain stimulation method called Temporally Interfering Electric Fields Stimulation (TIEFS) affects brain activity and thinking in adults. TIEFS uses electrical currents applied to the scalp to influence brain activity without surgery.\n\nThe main questions this study aims to answer are:\n\n* How does TIEFS change brain signals measured with brain recordings?\n* Does TIEFS affect thinking abilities such as memory, language, movement, or perception?\n* Is TIEFS safe and well tolerated when used in people?\n\nThis study includes two groups of participants. One group includes adults with epilepsy who are already undergoing specialized brain monitoring as part of their medical care. The other group includes healthy adults with no history of seizures.\n\nParticipants will:\n\n* Receive brief sessions of TIEFS using electrodes placed on the scalp\n* Complete computer-based tasks that test memory, attention, language, or movement. Answer questions about how the stimulation feels\n* Have brain activity recorded during the study\n\nEach study visit lasts up to three hours and may occur in one or two sessions. Information from this study may help researchers better understand the human brain and support the development of future non-invasive brain stimulation treatments.",[428],"Epilepsy",[430],"Brain Stimulation","2026-06-16",{"date":368,"type":31},{"date":434,"type":31},"2025-04-16",{"date":436,"type":20},"2027-04-15",{"name":37,"class":38},{"id":439,"slug":4,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":444,"targetDuration":446,"studyType":405,"phases":4,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":336},"100625996","NCT07429890","REVIVE Prospective Registry Cohort Study","Prospective Observational Long-Term Safety and Effectiveness Registry of Patients Who Have Received Iltamiocel as Part of REVIVE Clinical Study in Patients With Tongue Dysphagia Resulting From the Treatment of Head and Neck Cancer","Inclusion Criteria:\n\n* Participants who have received iltamiocel as part of participation in the REVIVE clinical study for males and females with tongue dysphagia (TD) are eligible, provided the following criteria are fulfilled:\n\n  * Has completed the Month 24 visit in the REVIVE study.\n  * Has received iltamiocel as part of the blinded portion of the REVIVE study.\n  * Must be willing and able to comply with the study procedures, is able to understand all study requirements and must agree to read and sign the informed consent form prior to any study-related procedures.\n\nExclusion Criteria:\n\n* The following criteria will exclude participants from participation:\n\n  * Has received placebo as part of the blinded portion of the REVIVE study.\n  * Unable or unwilling to provide informed consent.\n  * Not available for, or willing to comply with the follow-up evaluations as required by the protocol.",{"count":445,"type":20},31,"5 Years","The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.",[449],"Oropharyngeal Dysphagia",[451,452,453],"Tongue","Dysphagia","Autologous",{"date":455,"type":31},"2026-06-18",{"date":457,"type":20},"2026-08-30",{"date":459,"type":20},"2032-06-30",{"name":37,"class":38},{"id":462,"slug":4,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":21,"phases":469,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":39},"100550963","NCT06453915","NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease","NeuroFLiPP - Parametric PET of Neuroinflammation in Fatty Liver Disease","Inclusion Criteria:\n\n* Participants \\>=18 years age\n* Participants who have or have planned a liver biopsy as:\n\n  * standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or\n  * as part of another Clinical Trials study for MASH, or\n  * standard of care prior to undergoing bariatric surgery\n  * Liver biopsy needs to be within 6 months of planned study-related imaging\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.\n* Uncontrolled claustrophobia\n* Body weight \\>225 kg due to limitations of the scanner bed\n* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy is available)\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n* Prisoners\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.\n* Pre-existing neurodegenerative disorders and dementia\n* Significant history of major skull concussion or repetitive head trauma\n* Currently on anticoagulant therapy\n* Metal implants (e.g., pacemaker) or claustrophobia that would preclude MRI scans",{"count":468,"type":20},12,[470],"EARLY_PHASE1","Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD.\n\nThe goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment",[473],"Positron Emission Tomography",{"date":455,"type":31},{"date":476,"type":31},"2025-04-30",{"date":478,"type":20},"2027-07",{"name":37,"class":38},{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":102,"sex":16,"minAge":17,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":21,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":39},"100519246","NCT06041048","Investigation of Locus Coeruleus Function in Sustained Attention","LC","Inclusion Criteria:\n\n* Between the ages of 18 - 60 years of age,\n* Typically developing, healthy adult\n\nExclusion Criteria:\n\n* History of schizophrenia, other forms of psychosis,\n* Specific or focal neurological disorder or severe alcohol or drug use disorder within the past 5 years\n* History of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants, or who have had recent history of myocardial infarction or unstable angina.\n* Volunteers with known hypersensitivity to modafinil or armodafinil or its inactive ingredients\n* Known allergy\u002Fsensitivity or any hypersensitivity to components of modafinil or its formulation\n* Inability to swallow tablets or tolerate oral medication;\n* Pregnant or nursing (participants will be required to have a negative pregnancy test)\n* Contraindication for MRI scanning (metal implants, pacemakers, metal foreign bodies, or pregnancy)\n* Use of psychotropic medication within the past week\n* Claustrophobic and not comfortable being in a small space may also not want to participate","60 Years",{"count":488,"type":20},40,[184],"The norepinephrine-producing locus coeruleus (LC) is thought to be central to a wide array of cognitive functions, like attention and goal pursuit, and has been implicated in dysfunctions including attention deficit hyperactivity disorder and schizophrenia. The goal of this proposal is to develop methods that permit measurement of activity in the human LC. Because the LC is small and located in the pons, the Investigators will use high resolution magnetic resonance imaging techniques tailored to the brainstem environment, including neuromelanin-sensitive images shown to delineate the LC, combined with pharmacological manipulation to confirm the location of functional activity.",[492],"Attention - no Condition is Being Assessed - Healthy Adults",{"date":455,"type":31},{"date":495,"type":31},"2023-10-01",{"date":497,"type":20},"2026-12-19",{"name":37,"class":38},{"id":500,"slug":4,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":102,"sex":16,"minAge":504,"maxAge":505,"enrollmentInfo":506,"targetDuration":4,"studyType":21,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":175},"100488261","NCT05637814","Dynamic Critical Congenital Heart Screening With Addition of Perfusion Measurements","Inclusion Criteria:\n\n* Age \\\u003C 22 days\n* Fetuses suspected to have congenital heart disease\n* Newborns with suspected\u002Fconfirmed critical congenital heart disease\n* Asymptomatic newborn undergoing SpO2 screening for CCHD\n\nExclusion Criteria:\n\n* Echocardiogram completed prior to enrollment as the newborn would then no longer be considered \"asymptomatic undergoing SpO2 screening for CCHD\"\n* For Newborns with confirmed\u002Fsuspected congenital heart disease (CHD): a) Patent ductus arteriosus and\u002For atrial septal defect\u002Fpatent foramen ovale without other defects, b) Corrective cardiac surgical or catheter intervention performed before enrollment or c) Current infusions of vasoactive medications other than prostaglandin therapy.","0 Minutes","21 Days",{"count":507,"type":20},320,[49],"The purpose of this study is to implement and externally validate an inpatient ML algorithm that combines pulse oximetry features for critical congenital heart disease (CCHD) screening.",[511],"Congenital Heart Disease",[513,514],"Machine Learning Algorithm","Pulse Oximetry",{"date":455,"type":31},{"date":517,"type":31},"2023-08-17",{"date":519,"type":20},"2027-12-31",{"name":37,"class":38},{"id":522,"slug":4,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":21,"phases":530,"briefSummary":531,"conditions":532,"keywords":535,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":39},"100630937","NCT07494162","Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS: Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS","Inclusion Criteria:\n\n* Ability to understand the purposes and risks of the trial and willingness to sign an informed consent form\n* Willingness and ability to comply with all protocol required procedures\n* Willingness to be randomized to receive either true acupuncture or sham acupuncture\n* Current self-report of chronic low back pain (cLBP) which has persisted for the past 3 months AND has resulted in pain on \\> 50% of days in the past 6 months\n* At least one palpable nodule or taut band in paraspinal, quadratus lumborum, or gluteal muscles\n* Reproduction of the patient's dominant pain with palpation of a muscle nodule or taut band\n* Predominantly paramedian pain (may be uni-lateral or bi-lateral)\n* Willing and able to lay motionless in a supine position at least twice, preferably thrice: 70-minute TB-PET\u002FCT scan\n* Willing and able to fast for at least 6 hours before and for the duration of the TB-PET\u002FCT scan\n* Willing to avoid strenuous exercise for 24 hours before the TB-PET\u002FCT scan visit\n* Willingness to practice effective contraception during the study.\n\nExclusion Criteria:\n\n* No Primary Care Physician\n* History of spine infection (discitis or osteomyelitis) or spine tumor\n* History of ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus\n* Confounding conditions that are known to be responsible for inducing pain\n* Implants at or in the region of the sites of interest\n* Diagnosis of any vertebral fracture in the last 6 months\n* Cauda equina syndrome or lumbar radiculopathy with functional motor deficit (strength\\\u003C4\u002F5 on manual motor testing)\n* Spinal implants (including fixation hardware, spinal cord stimulator, intra-thecal pumps, that are present in the region of the sites of interest)\n* Predominantly central pain\n* Pain below the knee\n* Positive straight leg raise test\n* Symptomatic hip arthritis\n* Uncontrolled claustrophobia\n* Pregnant or lactating participants\n* Body weight more than 225 kg (496 pounds) due to the weight limitation of the scanner bed\n* Prisoners\n* Inability to speak, read, and write in the English language\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n\nThat is, PET scans are not performed as part of a patient's treatment plan (e.g. standard of care, therapeutic purposes, or clinical care) and the research study did not intend to provide therapeutic benefit to the patient.\n\n•Any other criteria, which would make the participant unsuitable to participate in this study as determined by the Principal Investigator",{"count":529,"type":20},64,[49],"This study will evaluate the clinical and biological effects of acupuncture for chronic low back pain associated with myofascial pain syndrome (MPS).\n\nIn this randomized, participant- and assessor-blinded clinical trial, 64 adults with chronic low back pain due to MPS will be assigned to receive either true acupuncture or sham acupuncture for eight weeks. Participants will undergo total-body positron emission tomography\u002Fcomputed tomography (TB-PET\u002FCT) imaging and complete standardized pain and functional questionnaires at baseline and after treatment.\n\nThe study will evaluate whether acupuncture improves pain and function compared with sham treatment and whether TB-PET\u002FCT imaging can detect changes in myofascial tissue metabolism and perfusion that correspond with clinical outcomes.",[533,534],"Myofascial Pain Syndrome (MPS)","Chronic Low-back Pain (cLBP)",[536,537,538,539,540,541],"acupuncture treatment","Total-Body PET","FDG PET","Myofascial Pain Syndrome","Chronic Low Back Pain","Imaging Biomarkers","2026-06-15",{"date":239,"type":31},{"date":545,"type":31},"2026-05-18",{"date":547,"type":20},"2030-04",{"name":37,"class":38},{"id":550,"slug":4,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":554,"targetDuration":4,"studyType":21,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":563,"leadSponsor":564,"locationsCount":39},"100630421","NCT07487454","Sham-Controlled Rapid-Acting Neuromodulation for Depression","Inclusion Criteria:\n\n* English speaking\n* Able to provide informed consent\n* 18-65 years old\n* Meets MDD criteria per the Mini International Neuropsychiatric Interview (MINI)\n\nExclusion Criteria:\n\n* Unable to consent (due to medical condition, acute psychosis, substance use, etc)\n* Use of benzodiazepines or medications that would interfere with TMS treatment as per PI discretion\n* Active substance use or severe substance use that in the opinion of the PI would interfere with study participation\n* Untreated, active psychosis\n* Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study\n* Contraindications to receiving TMS and\u002For MRI as determined by screening questionnaires\n* Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies.",{"count":555,"type":20},264,[49],"The goal of this study is to learn whether 5 days of accelerated intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS), which is a non-invasive procedure that uses magnetic fields to stimulate brain activity, works to treat depression in adults.\n\nThe main questions it aims to answer are:\n\n* Does accelerated iTBS reduce depressive symptoms compared to sham (placebo) stimulation?\n* Are there measurable brain, biological, and digitally measured emotion changes associated with treatment response?\n\nParticipants will:\n\n* Be randomly assigned to receive either active iTBS or sham stimulation\n* Receive 10 stimulation sessions per day for 5 consecutive days (total of 50 sessions)\n* Complete MRI brain scans and EEG recordings before and after treatment\n* Provide blood and saliva samples to measure biological markers\n* Complete depression rating scales and questionnaires at baseline, during treatment, and at follow-up visits\n* Use a secure mobile app to record brief facial and vocal samples during the 5-day treatment and at follow-up visits\n* Return for follow-up visits at 1 week and at 1, 3, 6, and 12 months after treatment",[559],"Depression - Major Depressive Disorder","2026-06-12",{"date":431,"type":31},{"date":200,"type":20},{"date":354,"type":20},{"name":37,"class":38},{"id":566,"slug":4,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":21,"phases":573,"briefSummary":574,"conditions":575,"keywords":582,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":592,"locationsCount":39},"100613507","NCT07267494","Image-Guided Herniorrhaphy Study","Image-guided Herniorrhaphy Safety and Efficacy Pilot","Inclusion Criteria:\n\n* English-speaking adult with reducible hernia(s) or diastasis smaller than approximately 8 cm seeking treatment for their hernia but not able or willing to undergo traditional surgery (open, laparoscopic, or robotic)\n* Patient must be willing to undergo a novel 30- to 60-minute image-guided needle-based procedure\n\nExclusion Criteria:\n\n* Children, prisoners, and pregnant women (possibly requiring a pregnancy test on the day of the procedure)\n* Patients with a known reaction to local anesthetic or sedation medications or the suture material to be used\n* Patients with irreducible hernias\n* Patients with herniation not visible by ultrasound or CT\n* Patients that do not fit the diameter of a CT gantry or the weight limit of the procedural CT table\n* Patients without insurance or not willing to pay out-of-pocket for the study procedure",{"count":572,"type":20},30,[49],"This pilot clinical study will evaluate the safety and effectiveness of a new image-guided, needle-based approach for repairing abdominal or groin hernias in adults who are unable or unwilling to undergo traditional open or laparoscopic surgery. The technique uses ultrasound and, when needed, CT imaging to guide a hollow needle preloaded with barbed suture through the skin to close the hernia defect without large incisions or general anesthesia. Each participant will undergo one image-guided procedure and will be followed for eight months to assess complications and changes in hernia-related quality of life. Approximately thirty participants will be enrolled. The study aims to determine whether this minimally invasive approach is safe, feasible, and capable of improving hernia symptoms enough to justify a larger clinical trial",[576,577,578,579,580,581],"Hernia","Hernia Abdominal Wall","Ventral Hernia","Inguinal Hernia","Hiatal Hernia","Diastasis Recti",[583,584,585,586,587],"Image-guided herniorrhaphy","hernia","pilot study","quality of life","safety and feasability",{"date":431,"type":31},{"date":220,"type":20},{"date":591,"type":20},"2029-05-01",{"name":37,"class":38},""]